Position of the Transparency Council – Nucala (mepolizumab)
At its meeting on 20 January 2025, the Transparency Council adopted position No. 10/2025 on the evaluation of the drug Nucala (mepolizumab) within the framework of the drug program “Treatment of patients with hypereosinophilic syndrome (HES) (ICD-10: D72.11)”.
Publication of the position >>